In addition, CD147 overexpression has also been reported in several hematological malignancies, including acute myeloblastic leukemia, multiple myeloma, Hodgkin’s lymphoma, anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, and angioimmunoblastic T-cell lymphoma [17,18,19,20]. This evidence concerns the gene BSG and plasma cell myeloma.